21 research outputs found
Biological therapies for premature ovarian insufficiency: what is the evidence?
Premature Ovarian Insufficiency (POI) is a multi-factorial disorder that affects women of reproductive age. The condition is characterized by the loss of ovarian function before the age of 40 years and several factors have been identified to be implicated in its pathogenesis. Remarkably though, at least 50% of women have remaining follicles in their ovaries after the development of ovarian insufficiency. Population data show that approximately up to 3.7% of women worldwide suffer from POI and subsequent infertility. Currently, the treatment of POI-related infertility involves oocyte donation. However, many women with POI desire to conceive with their own ova. Therefore, experimental biological therapies, such as Platelet-Rich Plasma (PRP), Exosomes (exos) therapy, In vitro Activation (IVA), Stem Cell therapy, MicroRNAs and Mitochondrial Targeting Therapies are experimental treatment strategies that focus on activating oogenesis and folliculogenesis, by upregulating natural biochemical pathways (neo-folliculogenesis) and improving ovarian microenvironment. This mini-review aims at identifying the main advantages of these approaches and exploring whether they can underpin existing assisted reproductive technologies
Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation
BACKGROUND: Ovarian antibodies as detected by indirect immunofluorescence have been used to detect ovarian autoimmunity, but to our knowledge the rate of false positive findings using this method has never been reported. METHODS: Here we examine whether a commercially available ovarian antibody test system, using cynomologous monkey ovary, might be useful in the diagnosis of autoimmune premature ovarian failure. The test was performed in a blinded manner in 26 young women with 46,XX spontaneous premature ovarian failure, in 26 control women with regular menstrual cycles (matched for age, race, and parity) and 26 control men (matched for age and race). We also compared the frequency of other autoantibodies associated with ovarian autoimmunity. RESULTS: As a group young women with premature ovarian failure had an increased incidence of thyroid and gastric parietal cell autoimmunity (p < 0.05). Unexpectedly, however, nearly one third (31%) of normal control women had ovarian antibodies using the commercially available test. One half of young women with premature ovarian failure were found to have ovarian antibodies (P = 0.26). In our own laboratory we found similar results and we were unable to improve the specificity of the test. None of 26 men were found to have ovarian antibodies (P < 0.001). CONCLUSION: Since approximately one third of normal women were found to have ovarian antibodies using the system under study, we conclude that ovarian antibodies as detected by this indirect immunofluorescence method have poor specificity. The specificity of any ovarian antibody test should be established before it is used clinically
The Role of HCG in Implantation: A Mini-Review of Molecular and Clinical Evidence
Embryo implantation is a complex process involving continuous molecular cross-talk between the embryo and the decidua. One of the key molecules during this process is human chorionic gonadotropin (HCG). HCG effectively modulates several metabolic pathways within the decidua contributing to endometrial receptivity. Herein, a brief overview of the molecular mechanisms regulated by HCG is presented. Furthermore, we summarize the existing evidence regarding the clinical impact on reproductive outcomes after endometrial priming with HCG prior to embryo transfer. Although promising, further evidence is needed to clarify the protocol that would lead to beneficial outcomes
Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency
Low androgen levels occur in women with primary ovarian insufficiency(POI) and could contribute to mood and behavioral symptoms in this condition. We examined the effects of physiologic testosterone (T) replacement therapy added to standard estrogen/progestin replacement therapy (EPT) on quality of life, self-esteem, and mood in women with POI
The expression of Galectin-3 in endometrial cancer: a systematic review of the literature
Background Galectin-3 is part of a protein group called lectins and acts
as a multifunctional glycoprotein due to its expression location.
Galectin-3 is expressed by different human tissues. It plays a
significant role in carcinogenesis and the selection of tumor-related
physiological and pathological activities. Galectin-3 has been utilized
through the years as a diagnostic and prognostic marker for various
types of cancers. Methods and Results This review describes the outcomes
of some studies on the matter that were selected appropriately through a
review of the existing literature. These studies examined the levels of
Galectin-3 expression in endometrial carcinomas, the outcomes, and the
prognosis of these carcinomas. Two of the studies concluded that high
expression of Galectin-3 is associated with a tumor's histological
grade, type and depth. This enhanced nuclear Galectin-3 expression might
assist in progression to atypia and neoplasia. The other three on the
contrary concluded that malignant tumors had a decreased expression of
Galectin-3 and that Galectin-3 played a suppressive role in tumor
growth. Conclusions The part Galectin-3 might potentially have in
metastasis of cancers and the offering of a better prognosis for
patients is of high importance. To date, there is minimal literature
regarding the effects of Galectin-3 and more research is required
Hormonal and cytokine regulation of early implantation
Implantation of the blastocyst into the endometrium is a delicately
controlled process and a prerequisite for the furtherance of the
mammalian species. A complex network of molecules is involved in
preparing both the endometrium and blastocyst for a successful
interaction. However, the exact molecular steps are poorly understood.
Studies so far have shown that disruption of certain pathways results in
fertility defects. Impaired implantation is currently considered to be
the most important limiting factor for the establishment of viable
pregnancies in assisted reproduction. It is expected that elucidating
the molecular background of the process will enable accurate diagnosis
and effective treatment of infertility
Repeated implantation failure: a new potential treatment option
International audienceBackgroundPrevious studies have shown that the intrauterine administration of peripheral blood mononuclear cells (PBMC) may improve pregnancy outcome of women with repeated implantation failure (RIF). We have demonstrated that, during implantation, corticotropin-releasing hormone (CRH) plays a key role in facilitating endometrial decidualization and maternal-foetal immunotolerance. In the present preliminary study, we investigated whether the intrauterine administration of autologous CRH-treated PBMC can improve clinical pregnancy rates of women with RIF. MethodsForty-five (n=45) women with at least three failed in vitro fertilization (IVF) attempts and no previously reported clinical pregnancy were included in this crossover study. All women underwent controlled ovarian stimulation using the long GnRH agonist protocol. PBMC were isolated at day of oocyte retrieval, treated with CRH and administered in the uterine cavity at day 2, following oocyte retrieval. Blastocyst transfer was performed on day 5. ResultsFollowing the CRH-PBMC intrauterine administration, a significant increase was observed in the clinical pregnancy rate of this cohort of women with RIF (20/45 women had a clinical pregnancy; 4444%, P<10(-3)) compared to the previous null clinical pregnancy rate prior to the intervention. ConclusionThe current findings support a possible role for the intrauterine administration of autologous CRH-treated PBMC in treating women with RIF. Further randomized controlled trials are needed to investigate the efficacy of this intervention
Reverse Onco-Cardiology: What Is the Evidence for Breast Cancer? A Systematic Review of the Literature
Breast cancer and cardiovascular diseases (CVD) represent significant global health challenges, with CVD being the leading cause of mortality and breast cancer, showing a complex pattern of incidence and mortality. We explore the intricate interplay between these two seemingly distinct medical conditions, shedding light on their shared risk factors and potential pathophysiological connections. A specific connection between hypertension (HTN), atrial fibrillation (AF), myocardial infarction (MI), and breast cancer was evaluated. HTN is explored in detail, emphasizing the role of aging, menopause, insulin resistance, and obesity as common factors linking HTN and breast cancer. Moreover, an attempt is made to identify the potential impact of antihypertensive medications and highlight the increased risk of breast cancer among those women, with a focus on potential mechanisms. A summary of key findings underscores the need for a multisystem approach to understanding the relationship between CVD and breast cancer is also explored with a highlight for all the gaps in current research, such as the lack of clinical observational data on MI and breast cancer in humans and the need for studies specifically designed for breast cancer. This paper concludes that there should be a focus on potential clinical applications of further investigation in this field, including personalized prevention and screening strategies for women at risk. Overall, the authors attempt to provide a comprehensive overview of the intricate connections between breast cancer and cardiovascular diseases, emphasizing the importance of further research in this evolving field of cardio-oncology
Reproductive corticotropin releasing hormone, implantation, and fetal immunotolerance
The fundamental process of implantation involves a series of steps
leading to effective cross-talk between invasive trophoblast cells and
the maternal endometrium. The molecular interactions at the
embryo-maternal interface during the time of blastocyst adhesion and
subsequent invasion are not fully understood. Embryonic trophoblast and
maternal decidual cells produce corticotropin-releasing hormone (CRH)
and express Fas ligand ( FasL), a proapoptotic cytokine. Fas and its
ligand are pivotal in the regulation of immune tolerance. Trophoblast
and decidual CRH play crucial roles in implantation, as well as in the
anti-rejection process that protects the fetus from the maternal immune
system, primarily by killing activated T cells through Fas-FasL
interaction. The potential use of CRH antagonists is presently under
intense investigation. CRH antagonists have been used experimentally to
elucidate the role of CRH in blastocyst implantation and invasion, early
fetal immunotolerance, and premature labor